TBTore Børtveit

Tore Børtveit

*This is an algorithmically generated author record based on publicly available information.

Tore Børtveit has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Novel Concentrated Interdisciplinary Group Rehabilitation for Patients With Chronic Illnesses: Protocol for a Nonrandomized Clinical Intervention Study

    by Gerd Kvale, Bente Frisk, Marte Jürgensen, Tore Børtveit, Øystein Theodor Ødegaard-Olsen, Ane Wilhelmsen-Langeland, Bernt Bøgvald Aarli, Kristina Sandnes, Sidsel Rykken, Anne Haugstvedt, et al.

    Background: An aging population with a growing burden of chronic complex illnesses will seriously challenge the public health care system. Consequently, novel and efficacious treatment approaches are highly warranted. Based on our experiences with concentrated treatment formats for other health challenges, we developed a highly concentrated interdisciplinary group rehabilitation approach for chronic illnesses. Objective: We aim to explore the acceptability of the intervention and describe potential changes in functional impairment at follow-up. Methods: The cornerstones of the intervention are as follows: (1) prepare the patient for change prior to treatment, (2) focus on health promoting microchoices instead of symptoms, and (3) expect the patient to integrate the changes in everyday living with limited hands-on follow-up. The intervention will be delivered to patients with highly diverse primary symptoms, namely patients with low back pain, post–COVID-19 symptoms, anxiety and depression, and type 2 diabetes. Results: Recruitment started between August 2020 and January 2021 (according to the illness category). For initial 3-month results, recruitment is expected to be completed by the end of 2021. Conclusions: If successful, this study may have a substantial impact on the treatment of low back pain, post–COVID-19 symptoms, anxiety and depression, and type 2 diabetes, which together constitute a major socioeconomic cost. Further, the study may widen the evidence base for the use of the concentrated treatment format in a diverse group of medical conditions. International Registered Report Identifier (IRRID): DERR1-10.2196/32216


  • Open Access

    Evaluation of Novel Concentrated Interdisciplinary Group Rehabilitation for Patients With Chronic Illnesses: Protocol for a Nonrandomized Clinical Intervention Study (Preprint)

    by Gerd Kvale, Bente Frisk, Marte Jürgensen, Tore Børtveit, Øystein Theodor Ødegaard-Olsen, Ane Wilhelmsen-Langeland, Bernt Bøgvald Aarli, Kristina Sandnes, Sidsel Rykken, Anne Haugstvedt, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: An aging population with a growing burden of chronic complex illnesses will seriously challenge the public health care system. Consequently, novel and efficacious treatment approaches are highly warranted. Based on our experiences with concentrated treatment formats for other health challenges, we developed a highly concentrated interdisciplinary group rehabilitation approach for chronic illnesses. Objective: We aim to explore the acceptability of the intervention and describe potential changes in functional impairment at follow-up. Methods: The cornerstones of the intervention are as follows: (1) prepare the patient for change prior to treatment, (2) focus on health promoting microchoices instead of symptoms, and (3) expect the patient to integrate the changes in everyday living with limited hands-on follow-up. The intervention will be delivered to patients with highly diverse primary symptoms, namely patients with low back pain, post–COVID-19 symptoms, anxiety and depression, and type 2 diabetes. Results: Recruitment started between August 2020 and January 2021 (according to the illness category). For initial 3-month results, recruitment is expected to be completed by the end of 2021. Conclusions: If successful, this study may have a substantial impact on the treatment of low back pain, post–COVID-19 symptoms, anxiety and depression, and type 2 diabetes, which together constitute a major socioeconomic cost. Further, the study may widen the evidence base for the use of the concentrated treatment format in a diverse group of medical conditions.


  • Open Access

    Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder

    by Gerd Kvale, Bjarne Hansen, Kristen Hagen, Jonathan S. Abramowitz, Tore Børtveit, Michelle G. Craske, Martin E. Franklin, Svein Haseth, Joseph A. Himle, Sigurd Hystad, et al.

    Obsessive-compulsive disorder (OCD) is a debilitating psychiatric disorder with a lifetime prevalence of 1% to 2%,1,2 often with onset in childhood.3 Exposure and response prevention (ERP) and antidepressants are effective treatments,4,5 but response is mixed, indicating a need to develop more effective strategies. Based on experimental animal studies demonstrating that D-cycloserine (DCS), a partial N-methyl-D-aspartate receptor agonist,6,7 facilitates extinction learning, a number of human clinical trials have assessed whether ERP is augmented by DCS. While some early publications were promising,8,9 more recent meta-analyses show only small augmentation of DCS vs placebo (effect size, 0.25)10 and others no significant difference,11-13 including no significant difference in several studies involving patients with OCD.10,11,14-16 A study by Andersson et al17 concluded that DCS did not augment the effects of cognitive behavioral therapy, but found that antidepressants may interact with DCS to block its facilitating effect on fear extinction.